

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Aptus Pharma Ltd.
Connecting....Life



APTUS PHARMA LIMITED

CORPORATE IDENTITY NUMBER: U24230GJ2010PLC061957

Our Company was originally incorporated as "Aptus Pharma Private Limited", as a private limited company under the Companies Act, 1956, with the Registrar of Companies ("ROC"), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of our Company was changed to "Aptus Pharma Limited" and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. The Corporate Identification Number of our Company is U24230GJ2010PLC061957. For further details please refer to chapter titled "History and Certain Corporate Matters" beginning on Page No. 172 of the Prospectus.

Registered Office: Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427
Tel: +91 76004 27827; **E-mail id:** info@aptuspharma.com; **Website:** www.aptus-pharma.com
Contact Person: Mohini Hardikbhai Gandhi, Company Secretary and Compliance Officer;

OUR PROMOTERS: TEJASH MAHESHCHANDRA HATHI, CHATRABHUJ VALLABHBHAI BUTANI, KAPILBHAI HASMUKHBHAI CHANDARANA, GHANSHYAM VINUBHAI PANSURIYA, MILLY CHETAN LALSETA, RIDDHISH NATWARLAL TANNA, GAURANG RAMESHCHANDRA THAKKER, KRIPALIBEN MAYANK THAKKER AND KUNJAL PIYUSHBHAI UNADKAT

INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

Our Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model. We do not own any manufacturing plants but has entered into contract manufacturing agreement with seven manufacturing units, under various arrangements. Of these, we have formal loan and license agreements in place with two manufacturing units. The remaining production is carried out through informal arrangements with Other manufacturers, based on purchase orders (PO). We provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipidlowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 18,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF APTUS PHARMA LIMITED (THE "COMPANY" OR "APTUS" OR "ISSUER") AT AN ISSUE PRICE OF ₹ 70 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 60 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ 1302.00 LACS ("PUBLIC ISSUE") OUT OF WHICH 94,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ 70 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 65.80 LACS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 17,66,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ 70 PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 1236.20 LACS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 27.11 % AND 25.74 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 70/-*
THE ISSUE PRICE IS 7.00 TIMES OF THE FACE VALUE OF THE EQUITY SHARE
ANCHOR INVESTOR ISSUE PRICE: ₹ 70 PER EQUITY SHARE. THE ISSUE PRICE IS 7.00 TIMES OF THE FACE VALUE

BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: MONDAY, SEPTEMBER 22, 2025

BID/ ISSUE OPENED ON: TUESDAY, SEPTEMBER 23, 2025

BID/ ISSUE CLOSED ON: THURSDAY, SEPTEMBER 25, 2025

RISKS TO INVESTORS

Summary description of key risk factors based on materiality:

- **We do not have our own manufacturing facility for pharmaceutical products and we have to rely on third parties for contract manufacturing of the products sold by our Company.**
- **We are required to obtain, renew or maintain certain material statutory and regulatory permits and approvals required to operate our business, and if we fail to do so in a timely manner or at all, we may be unable to operate our business and our results of operations may be adversely affected.**
- **We derive a significant part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us or to terminate our contracts or purchase orders, our business, cash flows, financial condition and results of operations may be adversely affected.**
- **If we are unable to protect our intellectual property rights, our business, results of operations and financial condition may be adversely affected. Further, if our products were found to be infringing on the intellectual property rights of a third-party, we could be required to cease selling the infringing products, causing us to lose future sales revenue from such products and face substantial liabilities for infringement of intellectual property rights.**
- **Our Company may be exposed to product liability and other claims arising from defective medicines manufactured by third-party Contract Manufacturers, despite having manufacturing agreements in place, as indemnity terms are not pre-determined.**

Details of suitable ratios of the company for the latest full financial year

1. Basic and Diluted Earnings per Share (EPS)

Year ended	Basic & Diluted	
	EPS (in ₹)	Weights
March 31, 2025	6.37	3
March 31, 2024	5.32	2
March 31, 2023	1.30	1
Weighted Average (of the above three financial years)	5.18	

Note: Basic and Diluted EPS = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / weighted average no of equity shares outstanding during the year as per restated financials.

2. Net Asset Value (NAV)

Financial Year	₹ per share
Net Asset Value per Equity Share as of March 31, 2025 (Based on Actual Number of Shares)	13.93
Net Asset Value per Equity Share as of March 31, 2025 (Based on Weighted Average Number of Shares)	14.32
Net Asset Value per Equity Share after IPO	29.13
Issue Price	70
NAV Post Issue	
- At Floor Price	27.78
- At Upper Band	29.13

Note:
Net Asset Value has been calculated as per the following formula:
NAV = $\frac{\text{Net worth excluding revaluation reserve}}{\text{Outstanding number of Equity shares during the year}}$

3. Comparison with Industry Peers

Companies	Face Value (₹)	Current Market Price	P/E Ratio	EPS	RoNW (%)	Net Asset Value Per Share	Revenue from Operation	Total Income (₹ in Lakhs)
Aptus Pharma Limited**#	10	70	13.16	5.32	44.50%	13.93	2,455.77	2463.64
Peers								
Zota health care limited	10	1,207.50	382.12	3.16	2.72%	110.83	25,727.61	26,189.94
Sunrest Lifescience Limited	10	49.20	10.56	4.66	12.36%	37.72	3,312.24	3,312.29
Lincoln Pharmaceuticals Limited	10	556.10	13.53	41.11	12.26%	335.34	62,323.01	64,570.72

*CMP as on September 01, 2025 **

CMP of our company is considered as an Issue Price.

Amount taken from Restated Financials as on March 31, 2025

Source: <https://www.nseindia.com>

- Notes:**
- Considering the nature and size of the business of our Company the peers are not strictly comparable. However, above company is included for broad comparison
 - The figures for Aptus Pharma Limited are based on the restated standalone financial statements for the year ended March 31, 2025.
 - The figures are based on the Standalone financial statements for the year ended March 31, 2025 of Zota health care limited, Sunrest Lifescience Limited and Lincoln Pharmaceuticals Limited from the Annual reports of the Companies available from the website of the Stock Exchange and website of the Companies.
 - CMP of the peer group is as per the closing price as available on <https://www.nseindia.com>
 - P/E Ratio for the peer has been computed based on the closing market price of respective equity shares as on September 1, 2025 sourced from website of Stock Exchange as divided by the Basic/diluted EPS as applicable.
- 4. Financial Key Performance Indicators (KPI) of our company**

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024	For the year ended March 31, 2023
Revenue from operations ⁽¹⁾	2,455.77	1,785.70	1,389.73
Other Income	7.87	2.53	0.00
Total Income ⁽²⁾	2,463.64	1,788.23	1,389.73
EBITDA ⁽³⁾	475.70	149.30	57.46
EBITDA Margin (%) ⁽⁴⁾	19.31	8.35	4.13
Profit after Tax ⁽⁵⁾	309.96	79.81	19.43
Current Ratio ⁽⁶⁾	1.63	2.01	1.81
Debt Equity Ratio ⁽⁷⁾	1.49	3.00	2.28
Debt Service Coverage Ratio ⁽⁸⁾	8.84	5.06	2.37
Return on Capital Employed (%) ⁽⁹⁾	45.66	21.70	12.77
Net profit Ratio (%) ⁽¹⁰⁾	12.62	4.47	1.40
Return on equity (%) ⁽¹¹⁾	44.50	45.18	20.06

As certified by the Statutory auditor of our Company M/s A B K B & Co., Chartered Accountants, vide their certificate dated May 31, 2025 bearing UDIN: 25135216BMLXF8182

- Notes:**
- Revenue from operations is calculated as the sum of revenue from sale.
 - Total income is calculated as the sum of revenue from operations and other income for the period/year.
 - Operating EBITDA refers to earnings before interest, taxes, depreciation, amortisation, gain or loss from discontinued operations and exceptional items.
 - Operating EBITDA Margin refers to EBITDA during a given period as a percentage of Total income during that period.
 - Profit / (loss) for the period/ year is calculated as Total Income less Total Expenses less Total Tax expenses for the period/ year.

* Current Ratio is a liquidity ratio that measures our ability to pay short-term obligations (those which are due within one year) and is calculated by dividing the current assets by current liabilities.

(1) Debt to equity ratio is calculated by dividing the debt (i.e., borrowings (current and non-current) and current maturities of long-term borrowings) by total equity (which includes issued capital and all other equity reserves). (8) Debt Service Coverage Ratio is calculated by dividing the sum of Profit after Tax and interest amount by sum of the repayment of loan and Interest.

(9) RoCE (Return on Capital Employed) (%) is calculated as profit before tax plus finance costs divided by total equity, Reserves & Surplus and non current liabilities.

(10) Net Profit Ratio/Margin quantifies our efficiency in generating profits from our revenue and is calculated by dividing our net profit after taxes by our total revenue.

(11) Return on equity (RoE) is equal to profit for the year divided by the total equity and reserve and surplus during that period and is expressed as a percentage

5. Return on Net Worth (RoNW):

Year ended	RoNW (%)	Weight
March 31, 2023	20.06	1
March 31, 2024	45.18	2
March 31, 2025	44.50	3
Weighted Average	40.65	

Note:

Return on Net worth has been calculated as per the following formula:

1) Return on Net Worth (%) = Net Profit after tax attributable to owners of the Company, as restated / Net worth as restated as at year end.

2) Weighted average Net Worth = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.

PROPOSED LISTING: THURSDAY, SEPTEMBER 30, 2025*

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein 8,80,000 Equity Shares of Face Value of ₹ 10/- Each (not more than 50.00% of the Net Issue) shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors of which (a) one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and upto such lots equivalent to not more than ₹ 10 lakhs and (b) two-thirds of the Non- Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs provided under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion and not less than 35.00% of the Net Issue shall be available for allocation to Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 288 of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to BSE. For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before September 30, 2025*

*Subject to the receipt of listing and trading approval from the BSE SME ("BSE SME").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Monday, September 22, 2025. The Company received a total of 4 Anchor Investor Application Forms from 4 Anchor Investors for 11,46,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 8,02,20,000/- . Out of the total 4 Anchor Investor Application Forms, No Anchor Investor Application Forms were received from Domestic Mutual Funds. A total of 5,28,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 70 per Equity Share (including a share premium of Rs 60.00 per Equity Share) aggregating to Rs. 3,69,60,000/-.

The Issue (excluding Anchor Investors Portion) received 12,218 Applications for 5,46,62,000 Equity Shares (before technical rejections) resulting in 41.04 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of times Subscribed	Amount (Rs.)
1	Individual Investors	4,952	1,98,08,000	6,20,000	32	1,38,60,92,000
2	Non-institutional Investors (More than ₹ 0.2 million and upto ₹1 million)	347	22,56,000	88,000	26	15,79,20,000
3	Non-institutional Investors (above ₹1 million)	333	55,82,000	1,78,000	31	39,07,40,000
5	Qualified Institutional Bidders (excluding Anchors Investors)	2	4,30,000	3,52,000	1	3,01,00,000
6	Market Maker	1	94,000	94,000	1	65,80,000
	Total	5,635	2,81,70,000	13,32,000	21	1,97,14,32,000

Final Demand

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	65.00	168000	0.31	168000	0.31
2	66.00	24000	0.04	192000	0.35
3	67.00	4000	0.01	196000	0.36
4	68.00	24000	0.04	220000	0.40
5	69.00	36000	0.07	256000	0.47
6	70.00	5446000	99.53	54662000	100.00
	Total	54662000	100.00		

Continued to next page.....

Continued from previous page...

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on September 26, 2025.

1) **Allotment to Individual Investors (After Technical Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 70/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 31.43 times. The total number of Equity Shares Allotted in this category is 6,20,000 Equity Shares to 155 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sl no	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	4,000	4,872	100.00	1,94,88,000	100.00	4,000	7 : 220	6,20,000
	TOTAL	4,872	100.00	1,94,88,000	100.00			6,20,000

2) **Allotment to Non-Institutional Investors- Above Rs. 2 Lakhs and Upto Rs.10 Lakhs (After Technical Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 70/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 25.27 times. The total number of Equity Shares Allotted in this category is 88,000 Equity Shares to 14 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/allotted
1	6000	312	90.96	18,72,000	84.17	6,000	1 : 24	78,000
2	8000	9	2.62	72,000	3.24	6,000	0:0	0
3	10000	5	1.46	50,000	2.25	6,000	0:0	0
4	12000	4	1.17	48,000	2.16	6,000	0:0	0
5	14000	13	3.79	1,82,000	8.18	6,000	1 : 13	6000
6	8000 to 14000 (Allottees)	-	0.00	-	0.00	6,000	1 : 1	4000
	Total	343	100.00	22,24,000	100.00			88,000

Please Note : 2 (Two) lot of 2000 shares have been allocated to All the 1 Successful Allottees from Category 8000 to 14000 (except Category 6000).

3) **Allotment to Non-Institutional Investors- Above Rs.10 Lakhs (After Technical Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 70/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 30.64 times. The total number of Equity Shares Allotted in this category is 1,78,000 Equity Shares to 29 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. no	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/allotted
1	16000	307	94.46	49,12,000	90.06	6,000	28:307	1,68,000
2	18000	10	3.08	1,80,000	3.30	6,000	1:10	6,000
3	20000	2	0.62	40,000	0.73	6,000	0:0	0
4	22000	1	0.31	22,000	0.40	6,000	0:0	0
5	24000	1	0.31	24,000	0.44	6,000	0:0	0
6	36000	1	0.31	36,000	0.66	6,000	0:0	0
7	70000	2	0.62	1,40,000	2.57	6,000	0:0	0
8	100000	1	0.31	1,00,000	1.83	6,000	0:0	0
9	4000 Additional share will be allotted to successful allottees from Sr. no. 1 to 8 = 4000 shares				in ratio of 2:29	1,000	2 : 206	2,000
	TOTAL	325	100.00	5454000	100.00			1,78,000

Sr. no	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/allotted
1	16000	307	94.46	49,12,000	90.06	6,000	28:307	1,68,000
2	18000	10	3.08	1,80,000	3.30	6,000	1:10	6,000
3	20000	2	0.62	40,000	0.73	6,000	0:0	0
4	22000	1	0.31	22,000	0.40	6,000	0:0	0
5	24000	1	0.31	24,000	0.44	6,000	0:0	0
6	36000	1	0.31	36,000	0.66	6,000	0:0	0
7	70000	2	0.62	1,40,000	2.57	6,000	0:0	0
8	100000	1	0.31	1,00,000	1.83	6,000	0:0	0
9	4000 Additional share will be allotted to successful allottees from Sr. no. 1 to 8 = 4000 shares				in ratio of 2:29	1,000	2 : 206	2,000
	TOTAL	325	100.00	5454000	100.00			1,78,000

Place: Ahmedabad
Date: September 29, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF APTUS PHARMA LIMITED.

Disclaimer: APTUS PHARMA LIMITED (is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Gujarat on September 26, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/market-data/all-upcoming-issues-ipo>, and is available on the websites of the BRLM at www.ifinservices.in. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 28 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

MMTP PROJECTS PRIVATE LIMITED
CIN: U45309MH2022PTC434673
Regd. Office : 158, Dani Corporate Park, Vidyanagari Marg, Kalina, Santacruz(East), Vidyanagari, Mumbai, Maharashtra, India, 400098
E-mail ID : vopp12@edelweissalts.com | Contact No: 9819902525

Form NO. CAA. 2
[Pursuant to Section 230(3) and rule 6 and rule 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016]
BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, BENCH AT MUMBAI
COMPANY SCHEME APPLICATION NO. C.A.C.A.A./157/MB/2025
In the matter of the Companies Act, 2013
AND
In the matter of Sections 230 read with Section 232 of the Companies Act, 2013 and other applicable provisions of the Companies Act, 2013
AND
In the matter of Scheme of Amalgamation of Viridis Office Park 2 Private Limited ("Transferor Company") with MMTP Projects Private Limited ("Transferee Company") and their respective shareholders

MMTP Projects Private Limited,
a company incorporated under the provisions of Companies Act, 2013 having its registered office at 158, Dani Corporate Park, Vidyanagari Marg, Kalina, Santacruz (East), Mumbai - 400098, CIN: U45309MH2022PTC434673

NOTICE AND ADVERTISEMENT OF THE TRIBUNAL CONVENED MEETING OF UNSECURED CREDITORS OF THE APPLICANT COMPANY
Notice is hereby given that by an order dated 9th day of September, 2025, the Mumbai Bench of the National Company Law Tribunal ("Tribunal") has directed meeting to be held of the unsecured creditors of the Applicant Company ("Unsecured Creditors") to be held through VC/OAVM ("Meeting"), for the purpose of considering, and if thought fit, approving with or without modification, the arrangement embodied in the Scheme of Amalgamation of Viridis Office Park 2 Private Limited ("Transferor Company") with MMTP Projects Private Limited ("Transferee Company") and their respective shareholders under the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act") and rules made thereunder.
In pursuance of the said order and as directed therein further notice is hereby given that meeting of the unsecured creditors of the Applicant Company be convened and held on Monday, 3rd day of November, 2025 at 11 a.m. IST through Video Conferencing/Other Audio Visual Means ("VC/OAVM").
In pursuance of the Order, and as directed therein, notice of the Meetings along with corresponding annexures is sent to the Unsecured Creditors (i) via email whose names appear in the list of Unsecured Creditors as on the cut-off date decided by the Board of Directors of the Applicant Company and whose email addresses were registered with the Applicant Company and (ii) by way of RPAD/ Speed Post whose email ids are not available.
The Applicant Company has appointed MUFG Intime India Private Limited (Formerly "Link Intime India Private Limited") (referred to as "MUFG" hereafter) to provide the facility for participation in the Meetings through VC/OAVM facility and e-voting during the Meetings (wherever applicable).
A copy of the Notice along with the Explanatory Statement including Annexures can also be obtained free of charge from the registered office of the Applicant Company on all working days during business hours up to the date of the Meetings and the same will be available for inspection in electronic mode. The Unsecured Creditors can inspect the same up to the date of Meeting, by sending an e-mail to the Applicant Company at vopp12@viridisofficeparks.in.
In case you have any queries or issues regarding attending Meetings and e-voting, you may contact the helpdesk by sending a request at instameet@in.pmms.mufg.com or contact on:- Tel: 022 - 4918 6000 / 4918 6175. Creditors may also write to the Applicant Company at the email address vopp12@viridisofficeparks.in.
Since the Meetings of the Unsecured Creditors of the Applicant Company are being held through VC/ OAVM, the physical attendance of such creditors of the Applicant Company has been dispensed with. Hence, please note that the facility of appointing proxy(ies) by them will not be available.
The Tribunal has appointed Mr. Punit Kumar Goyal and failing him Mr. Mitesh Shah as Chairman of the meeting of unsecured creditors. The abovementioned Scheme, if approved in the meeting, will be subject to the subsequent approval of the Tribunal and such other approvals, permissions and sanctions from any other regulatory or statutory authority(ies) as may be deemed necessary and as contemplated in the Scheme.
The Tribunal has appointed Ms. Vineeta Patel, as scrutinizer (the "Scrutinizer") to scrutinize the voting through electronic means prior to the Meeting and also at the Meeting in a fair and transparent manner.
The Unsecured Creditors are requested to attend the Meeting, through the mode and the day, date and time as stated above. Attendance of the Unsecured Creditors of the Applicant Company participating in the Meetings through VC/ OAVM facility shall be counted for the purpose of reckoning the quorum under Section 103 of the Act. In case the required quorum as stated above is not present at the commencement of the Meeting, the Meeting shall be adjourned for 30 minutes, and thereafter, the Creditors present shall be deemed to constitute the quorum.
Voting in case of body corporate shall be permitted, provided the prescribed form/ authorization is filed with the Scrutinizer at cs.vineetapatel05@gmail.com in with a copy marked to the Applicant Company at vopp12@viridisofficeparks.in not later than 48 (forty-eight) hours before the start of the respective Meetings as required under Rule 10 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016.
The voting rights of the Unsecured Creditors shall be in proportion to the amount due/ debt in the name of the Unsecured Creditors of the Applicant Company as on the cut-off date.
An Unsecured Creditor, whose name is recorded in the records of the Applicant Company as on the cut-off date, shall only be entitled to avail the facility of voting and attend the aforesaid Meeting of the Unsecured Creditors. A person who is not an Unsecured Creditor of the Applicant Company as on the cut-off date should treat notice for information purpose only. Votes should be casted in the manner described in the instructions of the notice.
The results of the voting for the above Meeting shall be announced in accordance with the regulatory requirements or as prescribed by the Hon'ble Tribunal upon receipt of Scrutinizer's report.

For MMTP Projects Private Limited

Sd/-
Date : September 29, 2025
Place : Mumbai

Mr. Punit Kumar Goyal
Chairperson appointed for the Meeting

PUBLIC NOTICE TO WHOMSOEVER IT MAY CONCERN
This is to inform the General Public that following share certificate of **LARSEN & TOUBRO LIMITED** having its Registered Office at L&T House, Ballard Estate, Narottam Morarjee Marg, Mumbai-400001 registered in the name of the following Shareholder/s have been lost by them.

Name of Shareholder	Cert. No.	Folio No.	Distinctive Nos.	No. of Shares
LATE. Ms. SHAKUNTALA KANTIL SHROFF (DECEASED)	379262	71171892	580591137-580591336	200 FV: 2/- Each

The Public are hereby cautioned against purchasing or dealing in any way with the above referred share certificates.

Any person who has any claim in respect of the said share certificate/s should lodge such claim with the Company or its Registrar and Transfer Agents **KFIN TECHNOLOGIES LTD., Selenium Tower-B, Plot 31-32, Gachibowli, Financial District, Hyderabad-500032**, within 15 days of publication of this notice after which no claim will be entertained and the Company shall proceed to issue Duplicate Share Certificate/s.

Place: Mumbai
Date: 29/09/2025

Name of Legal Claimant/Applicant:
SHROFF BHADRESH KANTIL

PUBLIC NOTICE
NOTICE OF SURRENDER OF REGISTRATION AS INVESTMENT ADVISER OF ABANS COMMODITIES (I) PRIVATE LIMITED
To Whomsoever It May Concern,
Notice is hereby given that Abans Commodities (I) Private Limited, having SEBI Registration Number INA100015285 and BSE IA Enlistment Number 1472, intends to surrender its certificate of registration granted by the Securities and Exchange Board of India (SEBI) to act as an Investment Adviser.
Any person having any claims, complaints, or grievances in respect of the above-mentioned Investment Adviser may submit the same at the SEBI Complaint Redressal Portal at <https://scores.sebi.gov.in>.
This notice is being issued in accordance with SEBI's requirements for surrender of registration.
For Abans Commodities (I) Private Limited
Sd/-
Shivshankar Singh
Director
DIN: 07787861
Place: Mumbai
Date: 29-09-2025

PUBLIC NOTICE TO WHOMSOEVER IT MAY CONCERN
This is to inform the General Public that following share certificates of **NICHOLAS PIRAMAL INDIA LIMITED**, having its Registered Office at Piramal Ananta, Agastya Corporate Park, Opp. Fire Brigade,Kamani Junction, LBS Marg, Kurla (W), Mumbai, 400070 registered in the name of the following shareholder have been lost by him.

Name of the Shareholder/s	Folio No.	Certificate Nos.	Distinctive Numbers	No. of Shares
RAJESH VADILAL MEHTA	RB00167	279351	20029392 To 20029441	125 FV
JAYSHRI RAJESH MEHTA		279352	20029442 To 20029491	10/-
		279353	20029492 To 20029516	Each Share

The Public are hereby cautioned against purchasing or dealing in any way with the above referred share certificates.

Any person who has any claim in respect of the said share certificate/s should lodge such claim with the Company or its Registrar and Transfer Agents **MUFG Intime India Private Limited** 247 Park, C-101, L.B.S. Marg, Vikroli (W) Mumbai-400083 TEL: +918108116767 within 15 days of publication of this notice after which no claim will be entertained and the Company shall proceed to issue Duplicate Share Certificate/s.

Place: Mumbai
Date: 29/09/2025

Name of the Registered Shareholder/ Legal Claimant:
RAJESH VADILAL MEHTA & JAYSHRI RAJESH MEHTA,

FORM B
PUBLIC ANNOUNCEMENT
(Regulation 12 of the Insolvency and Bankruptcy Board of India (Liquidation Process) Regulations, 2016)

FOR THE ATTENTION OF THE STAKEHOLDERS OF AGRIMAS CHEMICALS LIMITED -IN LIQUIDATION

Sl.No.	PARTICULARS	DETAILS
1.	Name of the Corporate Debtor	Agrimas Chemicals Limited
2.	Date of incorporation of Corporate Debtor	03/07/1973
3.	Authority under which Corporate Debtor is incorporated/ registered	Registrar of Companies- Mumbai
4.	Corporate Identity No. / Limited Liability Identification No. of corporate debtor	U99999MH1973PLC016649
5.	Address of the registered office and principal office (if any) of Corporate Debtor	Registered office- H2, MIDC Ind. Estate, Talaja, Dist. Raigad-410208, Maharashtra Corporate Office- 602, 6th Floor, ILD Trade Centre Sector- 47 Gurugram- 122018, Haryana
6.	Date of closure of Insolvency Resolution Process	25.09.2025
7.	Liquidation commencement date of Corporate Debtor	25.09.2025
8.	Name and registration number of the insolvency professional acting as Liquidator	Sanjay Kumar Gupta IBBI/PA-003/ICAI-N-00417/2022-2023/14117
9.	Address and e-mail of the Liquidator, as registered with the Board	Flat no. 503, Block-9, Fifth Floor, Opal Orris , Misrod, Huzur ,Near Rukmani College , Bhopal ,Madhya Pradesh ,462026 an93.jp@gmail.com
10.	Address and e-mail to be used for correspondence with the Liquidator	Flat no. 503, Block-9, Fifth Floor, Opal Orris , Misrod, Huzur ,Near Rukmani College ,Bhopal , Madhya Pradesh ,462026 Email: Liq.AgrimasChemicals@gmail.com
11.	Last date for submission of claims	26.10.2025

Notice is hereby given that the National Company Law Tribunal, Mumbai-Bench-V has ordered the commencement of liquidation of Agrimas Chemicals Limited on 25.09.2025. The stakeholders of Agrimas Chemicals Limited are hereby called upon to submit their claims with proof on or before 26.10.2025 to the liquidator at the address mentioned against item No.10.

The financial creditors shall submit their claims with proof by electronic means only. All other creditors may submit the claims with the proof in person, by post or by electronic means.

Submission of false or misleading proof of claims shall attract penalties.

Date: 29 September 2025
Place: Bhopal

Sd/-
Sanjay Kumar Gupta
IBBI/PA-003/ICAI-N-00417/2022-2023/14117
AFA valid till 31 December 2025
Liquidator in the matter of Agrimas Chemicals Ltd - in Liquidation

4) **Allotment to QIBs excluding Anchor Investors (After Technical Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 70/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 1.22 times of QIB portion. As per the SEBI Regulations, Mutual Funds were Allotted 5% of the Equity Shares of QIB Portion available i.e., NIL Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e., 3,52,000 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 3,52,000 Equity Shares which were allotted to 2 successful QIB Investors. The category-wise details of the Basis of Allotment are as under:

Category	FI'S/BANK'S	MFS	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
QIB	-	-	-	-	-	3,52,000	-	3,52,000

5) **Allocation to Market Maker (After Technical Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹70/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 94,000 Equity Shares the total number of shares allotted in this category is 94,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. no	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ration of allottees to applicants	Total No. of shares allocated/allotted
1	94,000	1	100.00	94,000	100.00	94,000	1:1	94,000
	TOTAL	1	100.00	94,000	100.00			94,000

6) **Allotment to Anchor Investors (After Technical Rejections)**

The Company in consultation with the BRLM has allocated 5,28,000 Equity Shares to 4 Anchor Investors at the Anchor Investor issue price of Rs. 70/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

CATEGORY	FIS/BANKS	MFS	IC'S	NBFC'S	AIF	FPI/FPC	VC'S
ANCHOR	-	-	-	-	1,92,000	3,36,000	-

The Board of Directors of our Company at its meeting held on September 26, 2025 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/ mailed for unblocking of funds and transfer to the Public Issue Account on or before September 29, 2025 and payment to non-Syndicate brokers have been issued on September 29, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before September 17, 2025 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on September 30, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated September 26, 2025 ("Prospectus").

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, **BIGSHARE SERVICES PRIVATE LIMITED** at www.bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

BIGSHARE SERVICES PRIVATE LIMITED
Address: Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai – 400093
Tel No.: 022-62638200
Email: ipo@bigshareonline.com
Investor Grievance Email: investor@bigshareonline.com
Contact Person: Mr. Babu Rapheal C
SEBI Registration No.: INR000001385

On behalf of Board of Directors
FOR, APTUS PHARMA LIMITED
Sd/-
Mohini hardikbhai Gandhi
Company Secretary & Compliance Officer

E-Auction Sale Notice
(Under The Insolvency and Bankruptcy Code, 2016)
S V Distributors Private Limited (In Corporate Insolvency Resolution Process)
Regd office: 228, Keytoo Industrial Estate, Kondivita Road, J.B. Nagar, Andheri (E), Mumbai – 400059

DATE & TIME OF E-AUCTION: Monday, 06th October, 2025 from 4.00 PM to 5.00 PM
E-Auction of Sale of Inventory of S V Distributors Private Limited - In CIRP will be conducted on "As is where is basis", "As is what is basis", "Whatever there is basis" and "No recourse basis"

Block	Asset	Reserve Price * (INR)	Earnest Money Deposit (EMD) (INR)	Bid Incremental Amount (INR)
1.	Various types of Spirits at Custom Bonded Godown: 1.Dionysus Supply Chain Pvt. Ltd., A-31, Kohinur Industrial Complex, Opp.Hindalco, MIDC Talaja, Taluka Panvel, District Raigad –410208 MH 2.Dionysus Supply Chain Pvt. Ltd., Survey No. 4/1 & 4/2, Devichapada, Taluka Panvel, District Raigad – 410208 MH	6,00,00,000 (Rupees six crores only)	50,00,000 (Rupees fifty lacs only)	5,00,000 (Rupees five lacs only)

* Reserve Price excludes Excise, Custom, VAT and TCS and any other duties, cess, etc. as may be applicable.

Terms and Conditions of the E-Auction are as under:
1. Any additional information on E-Auction Sale shall be made available on request by writing to Resolution Professional on ip.svdpl@gmail.com or contact 9549940647.
2. Above inventory is kept at Taluka Panvel, District Raigad in Custom Bonded warehouses. Interested bidder can visit the premises for inspection with prior appointment during office hours from September 29, 2025 11.00 AM to October 04, 2025 4.00 PM
3. All above inventories are available on "As is where is basis", "As is what is basis", "Whatever there is basis", "No recourse basis" & "Ex-godown basis".
4. The intending bidders are required to deposit EMD by **05 October 2025 before 5.00 PM**.
5. The balance payment has to be made on or before **20 November 2025** and inventory shall be released upon receipt of balance bid amount.
6. In case the successful bidders fails to make the balance payment by **20 November 2025** then the EMD shall be forfeited.
7. All costs pertaining to registration, permits, duties, taxes shall be borne by the successful bidder.
8. The Resolution Professional has the absolute right to accept or reject any or all offer(s) or adjourn/postpone/cancel the E- Auction or withdraw any stocks or portion thereof or alter the terms of payments from the auction proceeding at any stage without assigning any reason therefor.
Sd/-
Krishna Chamadia
Resolution Professional – S V Distributors Private Limited
IBBI Registration Number: IBBI/PA-001/IP-P00694/2017-18/11220

Date: September 29, 2025
Place: Mumbai

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

For
Advertising in
TENDER PAGES
Contact
JITENDRA PATIL
Mobile No.:
9029012015
Landline No. :
67440215

THE BUSINESS DAILY.

FOR DAILY BUSINESS.

financialexpress.com